Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | CA2 | P00918 | 8/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27932944 | 0.84 | KAT6A (0.51) | LMNAKAT6AERCC1ERCC4MEN1 | |
| SCHEMBL478964 | 0.84 | KAT6A (0.51) | LMNAKAT6AERCC1ERCC4MEN1 | |
| SCHEMBL4881585 | 0.81 | CA12 (0.57) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL31010371 | 0.81 | KAT6A (0.52) | LMNAKAT6AMEN1KMT2ANAMPT | |
| SCHEMBL14372411 | 0.80 | KAT6A (0.60) | KAT6ACA1CA2CA9CA12 | |
| SCHEMBL29764447 | 0.79 | LMNA (0.64) | LMNACA1CA2CA9CA12 | |
| SCHEMBL5934873 | 0.78 | NOTUM (0.57) | LMNAKAT6AERCC1ERCC4MEN1 | |
| Sulfanilamide SCHEMBL28755036 | 0.77 | CA2 (0.50) | LMNAKAT6ACA1CA2CA9 | |
| SCHEMBL5135419 | 0.77 | KAT6A (0.46) | LMNAKAT6AERCC1ERCC4MEN1 | |
| Hydrochloric Acid SCHEMBL6006151 | 0.77 | NOTUM (0.55) | LMNAKAT6AERCC1ERCC4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | LMNA 3466/4885KAT6A 3241/4885CA1 4868/4885 |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | LMNA 1520/4885KAT6A 3459/4885CA1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.